Precision medicine startup Aqtual has raised $31 million in an oversubscribed Series B financing to support commercialization of its cell-free DNA-based assay predicting patient response to rheumatoid arthritis (RA) therapies. The assay captures chronic disease biology to inform treatment planning. Currently recruiting over 1,300 participants in the PRIMA-102 observational clinical trial, Aqtual aims to complete enrollment by year-end. Initial proof-of-concept data was presented in 2023, with further insights and commercialization strategies expected at upcoming rheumatology and diagnostics conferences. CEO Diana Abdueva stated the funding positions the company to advance its pipeline and form new partnerships across disease areas.